Table 4 Pulmonary function test results and clinical symptoms for two groups of COVID-19 patients with pulmonary fibrosis
|  | Group Aa (N = 33) | Group Bb (N = 114) | P value |
|---|---|---|---|
Overall abnormalities ratio in pulmonary function test | 54.55% (18/33) | 66.67% (76/114) | 0.2841 |
Abnormal lung function ratioc | 18.18% (6/33) | 22.81% (26/114) | 0.7433 |
Obstructive disorder ratio | 6.06% (2/33) | 4.39% (5/114) | 0.9471 |
Restrictive disorder ratio | 3.03% (1/33) | 7.02% (8/114) | 0.6679 |
Small airway disorder ratio | 9.09% (3/33) | 11.40% (13/114) | 0.9535 |
MEF 25 decreased | 36.36% (12/33) | 40.35% (46/114) | 0.8333 |
Abnormal lung diffusion function | 6.06% (2/33) | 7.02% (8/114) | 0.8413 |
The patients with persistent PFT abnormalities and ongoing symptoms | 44.44% (8/18) | 44.74% (34/76) | 0.8094 |
Severe/critical patients ratio | 3.03% (1/33) | 24.56% (28/114) | 0.0128 |
Symptomatic patients ratio | 30.30% (10/33) | 43.86% (50/114) | 0.2324 |
Dyspnea | 3.03% (1/33) | 1.75% (2/114) | 0.8084 |
exercise limitation | 6.06% (2/33) | 8.77% (10/114) | 0.8887 |
Cough | 18.18% (6/33) | 14.91% (17/114) | 0.8546 |
Fatigue | 9.09% (3/33) | 21.05% (24/114) | 0.1910 |
chest tightness | 3.03% (1/33) | 7.89% (9/114) | 0.5587 |
Hyposmia | 0% (0/33) | 1.75% (2/114) | 0.9306 |
Ongoing O2 requirement | 0 | 0 | – |